Why hasn’t there been more progress in new Chagas disease drug discovery?

@article{Vermelho2019WhyHT,
  title={Why hasn’t there been more progress in new Chagas disease drug discovery?},
  author={Alane Beatriz Vermelho and Giseli Capaci Rodrigues and Claudiu T. Supuran},
  journal={Expert Opinion on Drug Discovery},
  year={2019},
  volume={15},
  pages={145 - 158}
}
ABSTRACT Introduction: Chagas disease (CD) is a neglected disease caused by the protozoan parasite Trypanosoma cruzi. In terms of novel drug discovery, there has been no progress since the 1960s with the same two drugs, benznidazole and nifurtimox, still in use. The complex life cycle, genetic diversity of T. cruzi strains, different sensitivities to the available drugs, as well as little interest from pharmaceutical companies and inadequate methodologies for translating in vitro and in vivo… Expand
18 Citations
Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery
TLDR
An overview of commercial drugs and those that have been evaluated in studies and clinical trials so far is presented and how proteochemometric (PCM) modeling and microcrystal electron diffraction (MicroED) can help in the case of the lack of a 3D protein structure is discussed. Expand
Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge.
TLDR
New drugs are urgently needed to tackle Chagas disease and the relevant aspects related to the lack of drugs are considered, the advances in tools for drug discovery are resumed, and the main features to be taken into account to develop new effective drugs are discussed. Expand
Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
TLDR
Comparative appraisal of one preferred lead in a chronic infection mouse model, monitored by highly sensitive bioluminescence imaging, provided the first definitive evidence of (partial) curative efficacy with this promising nitroimidazooxazine class. Expand
Delivery of Antisense DNA into Pathogenic Parasite Trypanosoma cruzi Using Virus-Like Protein-Based Nanoparticles.
TLDR
The combination of high stability and capability to transfect and knock down gene expression without causing cell damage and death makes the protein C-BK12 a promising starting point for the further development of safe and effective carriers to deliver AONs into T. cruzi. Expand
In Vitro Susceptibility of Kinetoplastids to Celastroloids from Maytenus chiapensis
Leishmaniasis and Chagas are among the most significant neglected tropical diseases. Due to several drawbacks with the current chemotherapy, developing new antikinetoplastid drugs has become anExpand
The Use of Antioxidants as Potential Co-Adjuvants to Treat Chronic Chagas Disease
TLDR
The main mechanisms of mitochondrial biogenesis and the NRF2-KEAP1 activation pathway are discussed and the antioxidants used as co-adjuvant therapy to treat experimental Chagas disease are reviewed. Expand
Inhibition of the β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with sulphonamides
TLDR
The first sulphonamide inhibition study of TvaCA1 is reported, with a series of simple aromatic/heterocyclic primary sulphonamides as well as with clinically approved/investigational drugs for a range of pathologies (diuretics, antiglaucoma, antiepileptic, antiobesity, and antitumor drugs). Expand
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders
  • C. Supuran
  • Medicine
  • Journal of enzyme inhibition and medicinal chemistry
  • 2021
TLDR
Carbonic anhydrases are enzymes involved in a multitude of diseases, and their inhibitors are in clinical use as drugs for the management of glaucoma, epilepsy, obesity, and tumours, making multitargeting an effective and innovative approach for various pharmacological applications. Expand
Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors
  • C. Supuran
  • Chemistry, Medicine
  • Journal of experimental pharmacology
  • 2020
TLDR
One small molecule inhibitor, sulfonamide SLC-0111, is the most advanced candidate, having completed Phase I and being now in Phase Ib/II clinical trials for the treatment of advanced hypoxic solid tumors. Expand
Inhibition of the newly discovered β‑carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with inorganic anions and small molecules.
TLDR
The inhibition of TvaCA1 with inorganic anions and small molecules is investigated and it is observed that thiocyanate, cyanide, selenite,selenite and divanadate are sub-millimolar inhibitors, whereas sulfamide, sulfate, phenylboronic acid and phenylarsonic acid are micromolar inhibitors. Expand
...
1
2
...

References

SHOWING 1-10 OF 136 REFERENCES
Current advances in drug discovery for Chagas disease.
TLDR
The aim of this review is to describe the advances in the medicinal chemistry of new anti-chagasic compounds reported in the literature in the last five years and present some important targets for the development of new synthetic compounds. Expand
Phenotypic screening approaches for Chagas disease drug discovery
TLDR
The application of technological advances to the field of Chagas disease has led to a variety of phenotypic assays that have not only changed the disease discovery landscape but have also helped to gain a better understanding of parasite/host interactions. Expand
High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery
TLDR
In vitro and in vivo early drug discovery approaches, which hopefully will contribute to bring better anti–T. Expand
Chagas Disease Drug Discovery
  • E. Chatelain
  • Biology, Medicine
  • Journal of biomolecular screening
  • 2015
TLDR
New developments in the Chagas field, including new technologies and tools now available, will be discussed, and a redesign of the current screening strategy during the discovery process is proposed. Expand
Fexinidazole: A Potential New Drug Candidate for Chagas Disease
TLDR
Fexinidazoles is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi strains, although parasite eradication was not achieved in all treated animals at the tested doses. Expand
Experimental and Clinical Treatment of Chagas Disease: A Review
TLDR
The literature emphasizes the urgent need for new therapies for acute and chronic CD, with the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology discussed. Expand
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery
TLDR
Clear differentiation between the nitro-aromatic drugs and posaconazole is shown in several assays, and suggests that in vitro there may be clinically relevant heterogeneity in the parasite population that can be revealed in long-term washout experiments. Expand
Two approaches to discovering and developing new drugs for Chagas disease.
This review will focus on two general approaches carried out at the Sandler Center, University of California, San Francisco, to address the challenge of developing new drugs for the treatment ofExpand
Translational challenges of animal models in Chagas disease drug development: a review
TLDR
An overview of animal models for Chagas disease is provided, and steps that could be undertaken to reduce variability and improve predictability of drug candidate efficacy are proposed. Expand
A New Experimental Model for Assessing Drug Efficacy against Trypanosoma cruzi Infection Based on Highly Sensitive In Vivo Imaging
TLDR
The exquisite sensitivity of this noninvasive murine model has been exploited to monitor parasite burden in real time throughout the chronic stage, has allowed the identification of the gastrointestinal tract as the major niche of long-term infection, and has demonstrated that chagasic heart disease can develop in the absence of locally persistent parasites. Expand
...
1
2
3
4
5
...